



KYTTARO

Pioneering Cardiovascular Therapeutics

A Cambridge Science Affiliate

Kyttaro Limited
BioEscalator
Innovation Building
Old Road Campus, Oxford
OX3 7FZ
www.kyttaro.com

Corporate Press Release

Monday, January 3, 2022

Kyttaro announces an exclusive worldwide licensing agreement with Oxford University Innovation – the research commercialization office of the University of Oxford. Novel therapeutic anti-inflammatory peptide technology developed in the laboratory of Shoumo Bhattacharya, British Heart Foundation Chair and Professor of Cardiovascular Medicine at the Wellcome Centre for Human Genetics.

Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease

LONDON, January 3, 2022 – Kyttaro Limited announced that it entered into a worldwide licensing agreement with Oxford University Innovation (OUI) to develop and commercialize an anti-inflammatory peptide technology platform that is based on naturally occurring proteins derived from ticks that have evolved over millennia to target and inhibit key components of the human immune system. The technology, which was developed by Prof. Shoumo Bhattacharya's group at the University of Oxford, with funding from the British Heart Foundation - the leading cardiovascular disease research charity in the UK - has the potential to treat a wide range of inflammatory conditions across multiple therapeutic areas including cardiovascular disease.

Atherosclerotic cardiovascular disease (ASCVD), such as coronary artery disease (CAD), is a leading cause of morbidity and mortality worldwide despite extensive use of existing ASCVD therapies (e.g. statins). It is estimated that CAD, which involves plaque formation in the blood vessels supplying the heart, is the most common heart disease in the US with 20M affected individuals and that CAD was responsible for c.360k US deaths in 2019. Inflammation has been identified as a key risk factor in ASCVD that promotes disease progression and is associated with ASCVD-related complication.



KYTTARO
Pioneering Cardiovascular Therapeutics

Kyttaro Limited
BioEscalator
Innovation Building
Old Road Campus, Oxford
OX3 7FZ
www.kyttaro.com

A Cambridge Science Affiliate

Emerging evidence from clinical studies showed that reducing inflammation on top of standard therapy has a clinical benefit and reduces cardiovascular events. Kyttaro's licensed peptide technology platform has the potential to tackle ASCVD-associated inflammation in a targeted and precise manner to reduce ASCVD risk and save patients.

Under the licensing agreement, OUI will provide Kyttaro with an exclusive, worldwide license covering all fields to develop and commercialize the peptide technology platform in return for undisclosed upfront, milestone and royalty payments. Kyttaro will advance the preclinical technology into the clinic in close collaboration with the inventor Prof. Bhattacharya, who is joining the Kyttaro team as member of the Scientific Advisory Board.

Prof. Bhattacharya is a world-leading cardiologist and academic who currently holds a British Heart Foundation Chair and is Professor of Cardiovascular Medicine at the Radcliffe Department of Medicine, University of Oxford. His primary role as British Heart Foundation Chair and his laboratory's focus at the Wellcome Centre for Human Genetics has been the development of novel therapeutics and targets (including the novel anti-inflammatory peptide technology). Prof. Bhattacharya received his medical degrees from the All India Institute of Medical Sciences in New Delhi and trained as cardiologist in Northwick Park and Hammersmith Hospitals in London. Prior to joining the University of Oxford in 1998, he received British Heart Foundation and NIH fellowships to work at the Dana-Farber Cancer Institute with Prof. David Livingston, the former deputy director and chairman of the Executive Committee for Research of the Harvard Institution.

Kyttaro, a Cambridge Science company, launched its lab in The Oxford BioEscalator on the Old Road Campus, a world-class center for medical research and clinical care, to advance the development of the pre-clinical peptide technology into the clinic. The BioEscalator is the biotech incubator of the University of Oxford and a world-class launching pad for high growth start-up and spin-out companies carrying out innovative science that has the potential to make a significant positive impact on healthcare in its broadest sense. The BioEscalator offers lab space and support to biotechs and



facilitates close collaboration between companies, academia and medical institutions associated with the University. The University of Oxford's Old Road Campus houses many world-leading institutes and academics that tackle a range of biomedical problems.

Douglas Eby, CEO of Kyttaro and Cambridge Science, commented: *"Cardiovascular disease, the world's leading cause of death, has been underinvested in for decades by the biopharmaceutical industry. The recent discovery of novel genetically validated ASCVD targets, new therapeutic modalities and the pivotal CANTOS trial, which established the efficacy of anti-inflammatory therapy in ASCVD, have the therapeutic class on the precipice of a new era in research and development. The potential for novel drugs, providing much-needed solutions for patients suffering from ASCVD, is very encouraging. Prof. Bhattacharya's exciting anti-inflammatory science is a great example of this movement in cardiovascular disease, and the Kyttaro team is looking forward to working with him and OUI to advance the technology into the clinic and ultimately to commercial status."*

Prof. Shoumo Bhattacharya, inventor of the technology and Principal Investigator at the Radcliffe Department of Medicine, University of Oxford, stated: *"I am looking forward to collaborating with the team at Kyttaro to accelerate the development of the anti-inflammatory platform technology that is based on naturally occurring proteins that have evolved in parasites for millions of years to circumvent the human body's immune response. This technology offers hugely promising treatment options for inflammatory conditions including cardiovascular disease."*

Dr. Abhimanyu Garg, leading lipid expert and Co-Chair of Kyttaro's Scientific Advisory Board, stated: *"Despite extensive use of ASCVD therapies (e.g. statins) that target lipids, a key ASCVD risk factor, ASCVD is a leading cause of mortality and morbidity that affects millions of people in the US and worldwide. There is an unmet need for novel therapies that target additional ASCVD risk factors such as inflammation and I believe this novel anti-inflammatory peptide technology platform has the potential to address this need and save patients from heart disease. I am also enthusiastic about Prof. Bhattacharya, a leading cardiologist and academic, joining Kyttaro's Scientific Advisory Board."*



KYTTARO

Pioneering Cardiovascular Therapeutics

Kyttaro Limited
BioEscalator
Innovation Building
Old Road Campus, Oxford
OX3 7FZ
www.kyttaro.com

A Cambridge Science Affiliate

ABOUT KYTTARO

Launched in Q2 2021 as an affiliate of Cambridge Science (CSC), Kyttaro Ltd is a UK-based pure-play biotech company that plans to develop innovative biologics to treat ASCVD and related metabolic and inflammatory conditions. Despite extensive use of therapies (e.g. cholesterol lowering statins), there is a high unmet need for new treatments that reduce ASCVD risk. Kyttaro aims to tackle several ASCVD risk factors such as triglycerides (TGs), cholesterol and inflammation. The company plans to complement the anti-inflammatory peptide technology platform with multiple advanced first-in-class biologics that lower TGs and / or improve cholesterol levels to reduce ASCVD. Kyttaro's clinical strategy focuses on rare and severe diseases associated with ASCVD risk factors related to TG and cholesterol levels as well as inflammation to establish safety and efficacy and ensure early market access and commercial success. Once Kyttaro establishes the efficacy of the assets in these rare and severe disorders, the company plans to enter the much larger ASCVD market through pharma partnerships to save people.

ABOUT CSC

Cambridge Science (CSC), which launched in 2018, is based in Kendall Square in Cambridge, Massachusetts. CSC is a new breed bioscience company with a mission to improve patient lives through the acceleration of translational research and creating long-term value for our shareholders. CSC is an operating entity pursuing internal R&D, in-licensing opportunities for advanced assets from major pharmaceutical companies and early stage technology from academia. CSC launches, finances and manages biotech companies commercializing advanced assets from pharma and / or novel technology developed by marquee principal investigators at the world's leading medical research institutions. Apart from its affiliate Kyttaro, CSC has already launched two emerging life science companies, Vivtex and Ovibio, and will continue to evolve into a diversified biotech company running multiple research and development, clinical and commercial programs. Through pursuing the venture creation business model, CSC has been able to leverage its top-tier science and network across scientific programs to create a differentiated value proposition for its shareholders. With the launch of Kyttaro, CSC is looking to repeat its early success in the US market by deploying some of the same competitive advantages to the UK biotech market.

Contact: Matthias Thurner, DPhil (SVP of Scientific Strategy): mthurner@kyttaro.com